Today’s drug discovery and the shadow of the rule of 5

References

• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [10.1016/S0169-409X(96)00423-1]. Adv Drug Deliv Rev. 1997;23(1–3):3–25. doi: 10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: s0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1. Adv Drug Delivery Rev. 2001 Mar 01;46(1–3):3–26.
   PubMed Web of Science ®Google Scholar
• Abad-Zapatero C. A sorcerer’s apprentice and the Rule of Five: from rule-of-thumb to commandment and beyond. Drug Discov Today. 2007 Dec;12(23–24):995–997. doi: 10.1016/j.drudis.2007.10.022
   PubMed Web of Science ®Google Scholar
• Benet LZ, Hosey CM, Ursu O, et al. BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev. 2016 Jun 1;101:89–98. doi: 10.1016/j.addr.2016.05.007
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today. 2004 Dec 01;1(4):337–341.
   Google Scholar
• Leeson PD, Young RJ. Molecular property design: does everyone get it? ACS Med Chem Lett. 2015 Jul 9;6(7):722–725. doi: 10.1021/acsmedchemlett.5b00157
   PubMed Web of Science ®Google Scholar
• Hartung IV, Huck BR, Crespo A, et al. Rules were made to be broken. Nat Rev Chem. 2023 Jan 01;7(1):3–4.
   PubMed Web of Science ®Google Scholar
• Stegemann S, Moreton C, Svanbäck S, et al. Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five. Drug Discovery Today. 2023 Feb 01;28(2):103344. doi: 10.1016/j.drudis.2022.103344
   PubMed Web of Science ®Google Scholar
• Doak BC, Kihlberg J. Drug discovery beyond the rule of 5 - Opportunities and challenges. Expert Opin Drug Discov. 2017 Feb 01;12(2):115–119.
   PubMed Web of Science ®Google Scholar
• Leo AJ. Calculating log Poct from structures. Chem Rev. 1993 Jun 01;93(4):1281–1306.
   Web of Science ®Google Scholar
• Moriguchi I, Hirono S, Liu Q, et al. Simple method of calculating octanol/water partition coefficient. Chem Pharm Bull (Tokyo). 1992;40(1):127–130. doi: 10.1248/cpb.40.127
   Web of Science ®Google Scholar
• Egbert M, Whitty A, Keseru GM, et al. Why some targets benefit from beyond rule of five drugs. J Med Chem. 2019 Nov 27;62(22):10005–10025. doi: 10.1021/acs.jmedchem.8b01732
   PubMed Web of Science ®Google Scholar
• Ermondi G, Vallaro M, Goetz G, et al. Updating the portfolio of physicochemical descriptors related to permeability in the beyond the rule of 5 chemical space. Eur J Pharm Sci. 2020 Apr 15;146:105274. doi: 10.1016/j.ejps.2020.105274
   PubMed Web of Science ®Google Scholar
• Shultz MD. Two decades under the influence of the rule of five and the changing properties of approved oral drugs. J Med Chem. 2019 Feb 28;62(4):1701–1714. doi: 10.1021/acs.jmedchem.8b00686
   PubMed Web of Science ®Google Scholar
• Brown DG, Wobst HJ. A Decade of FDA-Approved Drugs (2010–2019): trends and future directions. J Med Chem. 2021 Mar 11;64(5):2312–2338.
   PubMed Web of Science ®Google Scholar
• Leeson PD. Molecular inflation, attrition and the rule of five. Adv Drug Deliv Rev. 2016 Jun 1;101(Supplement C):22–33. doi: 10.1016/j.addr.2016.01.018
   PubMedGoogle Scholar
• Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies [Analysis]. Nat Rev Drug Discov. 2015 Jul;14(7):475–486.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2023 May 01;191:106774. doi: 10.1016/j.phrs.2023.106774
   PubMed Web of Science ®Google Scholar
• Doak BC, Over B, Giordanetto F, et al. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem Biol. 2014 Sep 18;21(9):1115–1142. doi: 10.1016/j.chembiol.2014.08.013
   PubMedGoogle Scholar
• Poongavanam V, Doak BC, Kihlberg J. Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space. Curr Opin Chem Biol. 2018 Jun;44:23–29. doi: 10.1016/j.cbpa.2018.05.010
   PubMed Web of Science ®Google Scholar
• DeGoey DA, Chen HJ, Cox PB, et al. Beyond the rule of 5: lessons learned from abbvie’s drugs and compound collection. J Med Chem. 2018 Apr 12;61(7):2636–2651. doi: 10.1021/acs.jmedchem.7b00717
   PubMed Web of Science ®Google Scholar
• Tinworth CP, Young RJ. Facts, patterns, and principles in drug discovery: appraising the rule of 5 with measured physicochemical data. J Med Chem. 2020 Sep 24;63(18):10091–10108. doi: 10.1021/acs.jmedchem.9b01596
   PubMed Web of Science ®Google Scholar
• Young RJ, Green DV, Luscombe CN, et al. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today. 2011 Sep;16(17–18):822–830. doi: 10.1016/j.drudis.2011.06.001
   PubMed Web of Science ®Google Scholar
• Garcia Jimenez D, Poongavanam V, Kihlberg J. Macrocycles in drug discovery─learning from the past for the future. J Med Chem. 2023 Apr 05;66(8):5377–5396. doi: 10.1021/acs.jmedchem.3c00134
   PubMed Web of Science ®Google Scholar
• Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem. 2009 Nov 12;52(21):6752–6756. doi: 10.1021/jm901241e
   PubMed Web of Science ®Google Scholar
• Leeson PD, Bento AP, Gaulton A, et al. Target-based evaluation of “drug-like” properties and ligand efficiencies. J Med Chem. 2021 Jun 10;64(11):7210–7230. doi: 10.1021/acs.jmedchem.1c00416
   PubMed Web of Science ®Google Scholar
• Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability–are too many aromatic rings a liability in drug design? Drug Discov Today. 2009 Nov;14(21–22):1011–1020. doi: 10.1016/j.drudis.2009.07.014
   PubMed Web of Science ®Google Scholar
• Ritchie TJ, Macdonald SJ, Young RJ, et al. The impact of aromatic ring count on compound developability: further insights by examining carbo-and hetero-aromatic and-aliphatic ring types. Drug Discovery Today. 2011;16(3–4):164–171. doi: 10.1016/j.drudis.2010.11.014
   PubMed Web of Science ®Google Scholar
• Fessard TC, Goncharenko K, Lefebvre Q, et al. Pushing the frontiers of accessible chemical space to unleash design creativity and accelerate drug discovery. CHIMIA Int J Chem. 2020;74(10):803–807. doi: 10.2533/chimia.2020.803
   PubMed Web of Science ®Google Scholar
• Shearer J, Castro JL, Lawson ADG, et al. Rings in clinical trials and drugs: present and future. J Med Chem. 2022 Jul 14;65(13):8699–8712.
   PubMedGoogle Scholar
• Winiwarter S, Ridderström M, Ungell AL, et al. 5.22 -use of molecular descriptors for absorption, distribution, metabolism, and excretion predictions. In: Taylor J Triggle D, editors. Comprehensive Medicinal Chemistry II. Oxford: Elsevier; 2007. p. 531–554.
   Google Scholar
• Rossi Sebastiano M, Doak BC, Backlund M, et al. Impact of dynamically exposed polarity on permeability and solubility of chameleonic drugs beyond the rule of 5. J Med Chem. 2018 May 10;61(9):4189–4202. doi: 10.1021/acs.jmedchem.8b00347
   PubMed Web of Science ®Google Scholar
• Goetz GH, Philippe L, Shapiro MJ. EPSA: a novel supercritical fluid chromatography technique enabling the design of permeable cyclic peptides. ACS Med Chem Lett. 2014 Oct 9;5(10):1167–1172. doi: 10.1021/ml500239m
   PubMed Web of Science ®Google Scholar
• Davis AM, Leeson PD. Physicochemical Properties. In: Ward S, and Davis A, editors. The handbook of medicinal chemistry. The Royal Society of Chemistry; 2023. p. 1–39. doi: 10.1039/9781788018982-00001
   Google Scholar
• Leeson PD, St-Gallay SA, Wenlock MC. Impact of ion class and time on oral drug molecular properties [10.1039/c0md00157k]. Med Chem Commun. 2011;2(2):91–105. doi: 10.1039/C0MD00157K
   Google Scholar
• Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol. 2011 Sep 19;24(9):1420–1456. doi: 10.1021/tx200211v
   PubMed Web of Science ®Google Scholar
• Young RJ. Physical Properties in Drug Design. In: Meanwell N, editor. Tactics in Contemporary Drug Design. Topics in Medicinal Chemistry. Berlin Heidelberg, Germany: Springer Berlin Heidelberg; 2014. p. 1–68. doi: 10.1007/7355_2013_35.
   Google Scholar
• Miller RR, Madeira M, Wood HB, et al. Integrating the impact of lipophilicity on potency and pharmacokinetic parameters enables the use of diverse chemical space during small molecule drug optimization. J Med Chem. 2020 Nov 12;63(21):12156–12170.
   PubMed Web of Science ®Google Scholar
• Di L, Kerns E, editors. Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization. 2nd ed. Boston, MA, USA: Academic Press; 2016.
   Google Scholar
• Ermondi G, Vallaro M, Goetz G, et al. Experimental lipophilicity for beyond Rule of 5 compounds. Future Drug Dis. 2019;1(1):FDD10. doi: 10.4155/fdd-2019-0002
   Google Scholar
• Caron G, Vallaro M, Ermondi G, et al. A fast chromatographic method for estimating lipophilicity and ionization in nonpolar membrane-like environment. Mol Pharm. 2016 Mar 7;13(3):1100–1110. doi: 10.1021/acs.molpharmaceut.5b00910
   PubMedGoogle Scholar
• Bunally S, Young RJ. The role and impact of high throughput biomimetic measurements in drug discovery. ADMET And DMPK. 2018;6(2):74–84. doi: 10.5599/admet.530
   Web of Science ®Google Scholar
• Landry ML, Crawford JJ. LogD contributions of substituents commonly used in medicinal chemistry. ACS Med Chem Lett. 2020 Jan 09;11(1):72–76.
   PubMed Web of Science ®Google Scholar
• Bunally SB, Luscombe CN, Young RJ. Using physicochemical measurements to influence better compound design. SLAS Discov. 2019 Sep;24(8):791–801. doi: 10.1177/2472555219859845
   PubMed Web of Science ®Google Scholar
• Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov. 2010 Mar;5(3):235–248. doi: 10.1517/17460441003605098
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Freire E. Finding a better path to drug selectivity. Drug Discovery Today. 2011 Nov 01;16(21):985–990.
   PubMed Web of Science ®Google Scholar
• Young RJ, Flitsch SL, Grigalunas M, et al. The time and place for nature in drug discovery. JACS Au. 2022 Nov 28;2(11):2400–2416. doi: 10.1021/jacsau.2c00415
   PubMedGoogle Scholar
• Wager TT, Hou X, Verhoest PR, et al. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem Neurosci. 2016 Jun 15;7(6):767–775.
   PubMed Web of Science ®Google Scholar
• Kenny PW. Hydrogen- bond donors in drug design. J Med Chem. 2022 Nov 10;65(21):14261–14275. doi: 10.1021/acs.jmedchem.2c01147
   PubMed Web of Science ®Google Scholar
• Goetz GH, Farrell W, Shalaeva M, et al. High throughput method for the indirect detection of intramolecular hydrogen bonding. J Med Chem. 2014 Apr 10;57(7):2920–2929. doi: 10.1021/jm401859b
   PubMed Web of Science ®Google Scholar
• Di LI, Kerns EH. Solubility issues in early discovery and HTS. In: Augustijns P Brewster M, editors Solvent systems and their selection in pharmaceutics and biopharmaceutics. biotechnology: pharmaceutical aspects. (NY): NY: Springer New York; 2007. p. 111–136.
   Google Scholar
• Barrett JA, Yang W, Skolnik SM, et al. Discovery solubility measurement and assessment of small molecules with drug development in mind. Drug Discovery Today. 2022 Jan 31;27(5):1315–1325.
   PubMed Web of Science ®Google Scholar
• Bergström CAS, Avdeef A. Perspectives in solubility measurement and interpretation. ADMET And DMPK. 2019;7(2):88–105. doi: 10.5599/admet.686
   Web of Science ®Google Scholar
• Sou T, Bergstrom CAS. Automated assays for thermodynamic (equilibrium) solubility determination. Drug Discov Today Technol. 2018 Jul;27:11–19. doi: 10.1016/j.ddtec.2018.04.004
   PubMedGoogle Scholar
• Jain N, Yalkowsky SH. Estimation of the aqueous solubility I: application to organic nonelectrolytes. J Pharm Sci. 2001 Feb;90(2):234–252. doi: 10.1002/1520-6017(200102)90:2<234:AID-JPS14>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Bergstrom CA, Wassvik CM, Johansson K, et al. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem. 2007 Nov 15;50(23):5858–5862. doi: 10.1021/jm0706416
   PubMed Web of Science ®Google Scholar
• Walz M-M, van der Spoel D. Systematically improved melting point prediction: a detailed physical simulation model is required [10.1039/C9CC06177K]. Chem Commun. 2019;55(80):12044–12047. doi: 10.1039/C9CC06177K
   PubMed Web of Science ®Google Scholar
• Hill AP, Young RJ. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. Drug Discov Today. 2010 Aug;15(15–16):648–655. doi: 10.1016/j.drudis.2010.05.016
   PubMed Web of Science ®Google Scholar
• Walters P The solubility forecast index. http://practicalcheminformaticsblogspotcom/2022/01/the-solubility-forecast-indexhtml.
   Google Scholar
• Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? [Perspective]. Nat Rev Drug Discov. 2008 Mar;7(3):205–220. doi: 10.1038/nrd2438
   PubMed Web of Science ®Google Scholar
• Di L, Artursson P, Avdeef A, et al. The critical role of passive permeability in designing successful drugs. ChemMedchem. 2020;15(20):1862–1874. doi: 10.1002/cmdc.202000419
   PubMed Web of Science ®Google Scholar
• Sugano K, Kansy M, Artursson P, et al. Coexistence of passive and carrier-mediated processes in drug transport [Perspective]. Nat Rev Drug Discov. 2010 Aug;9(8):597–614. doi: 10.1038/nrd3187
   PubMed Web of Science ®Google Scholar
• Price E, Kalvass JC, DeGoey D, et al. Global analysis of models for predicting human absorption: qSAR, in vitro, and preclinical models. J Med Chem. 2021 Jun 21;64(13):9389–9403.
   PubMed Web of Science ®Google Scholar
• Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability [10.1016/j.Bmcl.2009.03.109]. Bioorg Med Chem Lett. 2009 May 15;19(10):2844–2851.
   PubMed Web of Science ®Google Scholar
• O’ Donovan DH, De Fusco C, Kuhnke L, et al. Trends in molecular properties, bioavailability, and permeability across the bayer compound collection. J Med Chem. 2023 Feb 23;66(4):2347–2360.
   PubMed Web of Science ®Google Scholar
• Kell DB, Oliver SG. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion [Review]. Front Pharmacol. 2014 Oct 31;5:231. doi: 10.3389/fphar.2014.00231
   PubMed Web of Science ®Google Scholar
• O’Hagan S, Kell DB. Consensus rank orderings of molecular fingerprints illustrate the most genuine similarities between marketed drugs and small endogenous human metabolites, but highlight exogenous natural products as the most important ‘natural’ drug transporter substrates. ADMET And DMPK. 2017;5(2):85–125. doi: 10.5599/admet.5.2.376
   Google Scholar
• O′hagan S, Swainston N, Handl J, et al. A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs. Metabolomics. 2015 Apr 01;11(2):323–339.
   PubMed Web of Science ®Google Scholar
• Gally J-M, Pahl A, Czodrowski P, et al. Pseudonatural products occur frequently in biologically relevant compounds. J Chem Inf Model. 2021 Nov 22;61(11):5458–5468. doi: 10.1021/acs.jcim.1c01084
   PubMed Web of Science ®Google Scholar
• Ivanenkov YA, Zagribelnyy BA, Aladinskiy VA. Are we opening the door to a new era of medicinal chemistry or being collapsed to a chemical singularity? J Med Chem. 2019 Nov 27;62(22):10026–10043. doi: 10.1021/acs.jmedchem.9b00004
   PubMed Web of Science ®Google Scholar
• Hann MM, Keseru GM. Finding the sweet spot: the role of nature and nurture in medicinal chemistry [10.1038/nrd3701]. Nat Rev Drug Discov. 2012 Apr 30;11(5):355–365.
   PubMed Web of Science ®Google Scholar
• Tommasi R, Brown DG, Walkup GK, et al. Eskapeing the labyrinth of antibacterial discovery. Nat Rev Drug Discov. 2015 Aug 01;14(8):529–542.
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007 01;16(1):29–40. doi: 10.1038/nrd2201
   Google Scholar
• Kellenberger E, Hofmann A, Quinn RJ. Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs [10.1039/C1NP00026H]. Nat Prod Rep. 2011 Sep;28(9):1483–1492. doi: 10.1039/c1np00026h
   PubMed Web of Science ®Google Scholar
• Fullam E, Young RJ. Physicochemical properties and Mycobacterium tuberculosis transporters: keys to efficacious antitubercular drugs? [10.1039/D0MD00265H]. RSC Med Chem. 2021;12(1):43–56. doi: 10.1039/D0MD00265H
   Google Scholar
• O’Hagan S, Kell DB. Generation of a small library of natural products designed to cover chemical space inexpensively. Pharm Front. 2019;1(1):e190005.
   PubMedGoogle Scholar
• Lou K, Wassarman DR, Yang T, et al. IFITM proteins assist cellular uptake of diverse linked chemotypes. Science. 2022;378(6624):1097–1104. doi: 10.1126/science.abl5829
   PubMed Web of Science ®Google Scholar
• Hansch C, Bjorkroth JP, Leo A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design [10.1002/jps.2600760902]. J Pharm Sci. 1987 Sep;76(9):663–687. doi: 10.1002/jps.2600760902
   PubMed Web of Science ®Google Scholar
• Murray CW, Erlanson DA, Hopkins AL, et al. Validity of ligand efficiency metrics. ACS Med Chem Lett. 2014 Jun 12;5(6):616–618. doi: 10.1021/ml500146d
   PubMed Web of Science ®Google Scholar
• Johnson TW, Gallego RA, Edwards MP. Lipophilic efficiency as an important metric in drug design. J Med Chem. 2018 Aug 9;61(15):6401–6420. doi: 10.1021/acs.jmedchem.8b00077
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today. 2004 May 15;9(10):430–431. doi: 10.1016/S1359-6446(04)03069-7
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Keseru GM, Leeson PD, et al. The role of ligand efficiency metrics in drug discovery [Analysis]. Nat Rev Drug Discov. 2014 Feb;13(2):105–121.
   PubMed Web of Science ®Google Scholar
• Young RJ, Leeson PD. Mapping the efficiency and physicochemical trajectories of successful optimizations. J Med Chem. 2018 Aug 9;61(15):6421–6467. doi: 10.1021/acs.jmedchem.8b00180
   PubMed Web of Science ®Google Scholar
• Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: ways to make an impact, and why we are not there yet. Drug Discovery Today. 2021 Feb 01;26(2):511–524. doi: 10.1016/j.drudis.2020.12.009
   PubMed Web of Science ®Google Scholar
• Karageorgis G, Foley DJ, Laraia L, et al. Pseudo natural products—chemical evolution of natural product structure. Angew Chem Int Ed. 2021;60(29):15705–15723. doi: 10.1002/anie.202016575
   PubMed Web of Science ®Google Scholar
• Grigalunas M, Brakmann S, Waldmann H. Chemical evolution of natural product structure. J Am Chem Soc. 2022 Mar 02;144(8):3314–3329.
   PubMed Web of Science ®Google Scholar